systemic immune response to durvalumab concomitant with neoadjuvant chemotherapy in early stage tncb
Published 1 year ago • 79 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
1:13
predictive markers of response to durvalumab w/nab-paclitaxel doxorubicin/cyclophosphamide in tnbc
-
3:25
impact of radiation dose to immune cells in unresectable or stage iii nsclc in the durvalumab era
-
2:03
t-cell dynamics in response to neoadjuvant atezolizumab in early nsclc
-
2:00
matterhorn: neoadjuvant-adjuvant durvalumab and flot chemotherapy in resectable g/gej
-
6:22
refining which patients benefit from consolidation durvalumab for stage iii unresectable nsclc
-
3:48
poseidon: durvalumab /- tremelimumab chemo in 1l mnsclc
-
2:53
hudson: durvalumab combination therapies to overcome pd-l1 blockade resistance in advanced nsclc
-
11:11
extending durvalumab maintenance to special populations
-
1:31:16
pathologic response after neoadjuvant immunotherapy: facilitating progress in early-stage cancers
-
3:56
the use of the immunoscore in predicting the outcome of neoadjuvant chemotherapy in gi cancer
-
2:03
tremelimumab and durvalumab therapy in lung cancer
-
0:43
double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in nsclc
-
1:17
dr. chaft on investigational neoadjuvant immunotherapy approaches in nsclc
-
3:39
what is durvalumab’s future as a treatment option in lung cancer?
-
1:48
adjuvant and neoadjuvant chemo-io for uk patients with nsclc
-
1:45
association of pathologic complete response following neoadjuvant chemotherapy with longterm sur...
-
6:52
immunotherapy added to chemotherapy improves pathological complete response in early triple nega...
-
1:29
how can durvalumab be used in nsclc?
-
2:41
surgical experience after neoadjuvant chemo-immunotherapy